DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
30. April 2019 16:58 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 30, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer...
DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update
19. März 2019 16:30 ET
|
DiaMedica Therapeutics Inc.
Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019Acute ischemic stroke Phase II...
DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call
18. März 2019 13:56 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 18, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March...
DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019
12. März 2019 13:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz...
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
14. Februar 2019 08:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Feb. 14, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic...
DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders
22. Januar 2019 07:45 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled “Human Tissue Kallikrein In The Treatment Of Acute Ischemic...
DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange
09. Januar 2019 17:00 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 09, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) (TSX-V: DMA), a clinical stage biopharmaceutical company, announced today that it has applied to voluntarily...
UPDATE -- DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
03. Januar 2019 10:41 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease
03. Januar 2019 07:30 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Jan. 03, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica”) (NASDAQ:DMAC) (TSX-V:DMA) announced today that the U.S. Food and Drug Administration ("FDA") has accepted...
DiaMedica Closes Public Offering in the United States
11. Dezember 2018 17:30 ET
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, Dec. 11, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (“DiaMedica” or the “Company”) (NASDAQ:DMAC; TSXV:DMA), a clinical stage biopharmaceutical company, announced today that it...